Supplementary Table 1.
Demographics and Presenting Symptoms of LT Recipients With COVID-19 (n = 38)
| Characterisitics | Values |
|---|---|
| Age, y, median (range) | 63 (27–81) |
| Male sex, n (%) | 26 (68) |
| BMI, kg/m2, median (range) | 28.3 (18.7–50.0) |
| Ethnicity, n (%) | |
| White | 15 (39) |
| African American | 5 (13) |
| Hispanic | 14 (37) |
| Asian | 2 (5) |
| Other | 2 (5) |
| ABO blood type, n (%) | |
| A | 12 (32) |
| B | 9 (24) |
| AB | 5 (14) |
| O | 11 (30) |
| Residence, n (%) | |
| Manhattan | 3 (9) |
| Brooklyn | 7 (20) |
| Bronx | 4 (11) |
| Queens | 7 (20) |
| Staten Island | 3 (9) |
| Outside New York City | 5 (15) |
| Other state | 6 (17) |
| Indication for liver transplant, n (%) | |
| Alcohol-associated liver disease | 2 (5) |
| Hepatitis C | 16 (42) |
| Hepatitis B | 2 (5) |
| Autoimmune hepatitis | 2 (5) |
| Primary sclerosing cholangitis | 5 (13) |
| Primary biliary cholangitis | 1 (3) |
| Nonalcoholic fatty liver disease | 6 (16) |
| Polycystic liver disease | 2 (5) |
| Hemochromatosis | 1 (3) |
| Drug-induced liver injury | 1 (3) |
| Hepatocellular carcinoma, n (%) | 8 (21) |
| Type of LT, n (%) | |
| Liver alone | 32 (84) |
| Simultaneous liver-kidney | 6 (16) |
| Repeat transplantation | 2 (5) |
| Time from recent transplant, y, median (range) | 3.8 (0.02–28.2) |
| Symptoms, n (%) | |
| Asymptomatica | 2 (5) |
| Fever | 23 (61) |
| Cough | 21 (55) |
| Dyspnea | 13 (34) |
| Myalgias | 9 (24) |
| Malaise | 11 (29) |
| Rhinorrhea | 3 (8) |
| Gastrointestinal | 16 (42) |
| Anosmia | 1 (3) |
| Comorbidities, n (%) | |
| Hypertension | 24 (63) |
| Diabetes mellitus | 18 (47) |
| Cardiovascular disease | 11 (29) |
| Chronic kidney disease | 24 (63) |
| Malignancy | 2 (5) |
| Type of immunosuppression before admission, n (%) | |
| Tacrolimus | 37 (97) |
| Cyclosporine | 1 (3) |
| Everolimus | 1 (3) |
| Mycophenolic acid | 19 (50) |
| Corticosteroid | 15 (39) |
a
One patient was tested before endoscopy, and the other was tested to determine hospital cohorting.